Immunovant (IMVT) Common Equity (2018 - 2026)

Immunovant has reported Common Equity for 9 years, with the latest figure at $852.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 20.52% year-over-year to $852.6 million; the trailing twelve-month figure through Mar 2026 stood at $852.6 million (up 20.52% YoY), and the FY2026 full-year result was $852.6 million, up 20.52% from the prior year.
• Common Equity for Q1 2026 stood at $852.6 million, down from $986.1 million in the prior quarter.
• The five-year high for Common Equity was $986.1 million in Q4 2025, with the low at $251.8 million in Q3 2023.
• Historically, Common Equity has averaged $526.4 million across 5 years, with a median of $469.8 million in 2022.
• Annual changes were most pronounced in 2024 — Common Equity plunged 48.09% — and 2025, when it surged 179.66%.
• Immunovant's Common Equity stood at $414.7 million in 2022, then surged by 63.82% to $679.3 million in 2023, then sank by 48.09% to $352.6 million in 2024, then surged by 179.66% to $986.1 million in 2025, then dropped by 13.54% to $852.6 million in 2026.
• The last three Common Equity figures came in at $852.6 million (Q1 2026), $986.1 million (Q4 2025), and $519.7 million (Q3 2025), per Business Quant data.